We are excited to extend FREE invitation for Rznomics Inc.'s 1st Focused Meeting for Gene and RNA Therapeutics!
Rznomics Inc., is a RNA therapeutics company devoted to preclinical and clinical studies for rare and incurable diseases with trans-splicing ribozyme and its delivery vehicle, and our pipeline RZ-001 for hepatocellular carcinoma (HCC) and glioblastoma (GBM) has been approved for phase 1/2a clinical trial by U.S. FDA and Korean Ministry of Food and Drug Safety, and HCC combination 1b/2a IND submission to Korean MFDS has also been completed. Recently, we were selected as one of the 50 Best Companies in Technology Development for Small and Medium-sized Businesses by Korean Government Ministry.
